HX1408

Primary Objectives: Phase I Dose Escalation Study: 1. To evaluate the safety and tolerability of HX1408 tablets in patients with relapsed or progressive glioblastoma, and to determine the maximum tolerated dose and/or the recommended dose for Phase II. Phase II Dose Extension Study: 1. To evaluate the objective response rate and progression-free survival of HX1408 in patients with relapsed or progressive glioblastoma, assessed by a blinded independent review committee. Secondary Objectives: Phase I Dose Escalation Study: 1. To evaluate the pharmacokinetics of HX1408 in patients with relapsed or progressive glioblastoma; 2. To evaluate the investigator-assessed objective response rate, progression-free survival, disease control rate, and duration of response of HX1408 in patients with relapsed or progressive glioblastoma; 3. To evaluate the overall survival of HX1408 in patients with relapsed or progressive glioblastoma; Phase II Dose Extension Study: 1. To evaluate the safety of HX1408; 2. To evaluate the efficacy of HX1408 in patients with relapsed or progressive glioblastoma. 08. Investigator-assessed objective response rate and progression-free survival in patients with recurrent or progressive glioblastoma; 3. Evaluation of 6-month progression-free survival, disease control rate, and duration of response of HX1408 in patients with recurrent or progressive glioblastoma, as assessed by BIRC and investigators; 4. Evaluation of overall survival and 12-month survival of HX1408 in patients with recurrent or progressive glioblastoma; Evaluation of pharmacokinetic characteristics of HX1408 in patients with recurrent or progressive glioblastoma.